A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
Public ClinicalTrials.gov record NCT02120924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.
Study identification
- NCT ID
- NCT02120924
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Actavis Inc.
- Industry
- Enrollment
- 1,009 participants
Conditions and interventions
Conditions
Interventions
- Azelaic acid Drug
- Vehicle Drug
- Finacea Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2013
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2014
- Last update posted
- Jun 1, 2020
2013 – 2014
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 24 | Fremont | California | — | — |
| Site 22 | Santa Monica | California | — | — |
| Site 1 | Brandon | Florida | — | — |
| Site 3 | Fort Myers | Florida | — | — |
| Site 27 | Jacksonville | Florida | — | — |
| Site 19 | Miami | Florida | — | — |
| Site 9 | Miami | Florida | — | — |
| Site 29 | Miramar | Florida | — | — |
| Site 2 | Tampa | Florida | — | — |
| Site 15 | Chicago | Illinois | — | — |
| Site 4 | Plainfield | Indiana | — | — |
| Site 14 | Lake Charles | Louisiana | — | — |
| Site 17 | Glenn Dale | Maryland | — | — |
| Site 6 | Bay City | Michigan | — | — |
| Site 30 | Clinton Township | Michigan | — | — |
| Site 16 | Las Vegas | Nevada | — | — |
| Site 11 | Raleigh | North Carolina | — | — |
| Site 23 | Winston-Salem | North Carolina | — | — |
| Site 26 | Philadelphia | Pennsylvania | — | — |
| Site 12 | Warwick | Rhode Island | — | — |
| Site 28 | Simpsonville | South Carolina | — | — |
| Site 20 | Nashville | Tennessee | — | — |
| Site 21 | College Station | Texas | — | — |
| Site 5 | Dallas | Texas | — | — |
| Site 8 | El Paso | Texas | — | — |
| Site 13 | Houston | Texas | — | — |
| Site 7 | Katy | Texas | — | — |
| Site 18 | Salt Lake City | Utah | — | — |
| Site 10 | Norfolk | Virginia | — | — |
| Site 25 | University Place | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02120924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02120924 live on ClinicalTrials.gov.